injuries

MEISi-2 is a specific MEISi inhibitor that inhibits the meis luciferase reporter gene in vitro and induces MEIS-dependent hematopoietic stem cell maintenance and self-renewal, which can be used in research areas such as cardiac injury, hematopoietic problems, bone marrow transplantation and cancer.

Rocaglamide (Roc-A), isolated from the genus Aglaia, can be used to treat coughs, injuries, asthma, and inflammatory skin diseases. It is a potent inhibitor of NF-κB activation in T-cells.

Tirilazad mesylate (U 74006F) is a non-glucocorticoid, lipid peroxidation inhibitor with antiviral and neuroprotective activities. It confines intracellular intramembranous foci, attenuates spinal cord injuries induced by trauma, stroke, and ischemia/reperfusion injuries, inhibits toxins in dogs, and is used in the study of neurological disorders.

Nitrofurazone (Nitrofural; Furacilin) is an orally active nitroaromatic broad-spectrum antibiotic with activity against both Gram-positive and Gram-negative bacteria. It is commonly used for establishing breast cancer models.

3-Hydroxy-4-methoxyacetophenone (Acetoisovanillone) is an active P. spinosa extract. It possesses anti-inflammatory activity and prevented injuries due to administration of acetic acid in the colon.

Baclofen hydrochloride (4-amino-3-(4-chlorophenyl)butanoic acid hydron chloride) is a GAMMA-AMINOBUTYRIC ACID derivative that is a specific GABA-B RECEPTORS agonist. It is used in the treatment of MUSCLE SPASTICITY, especially that due to SPINAL CORD INJURIES. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission.

Keap1-Nrf2-IN-22 (compound 19) acts as a Keap1-Nrf2 inhibitor with a KD2 value of 42.2 nM. It is utilized in research focused on acute lung injury (ALI) and cerebral ischemia/reperfusion (I/R) injuries.

JNK-IN-19 (Compound Q8) is an inhibitor of c-Jun N-terminal kinase, utilized for the treatment and/or prevention of injuries prior to, during, or following surgery.

PARP1-IN-36 (compound 11) is a derivative of 4-carboxamide-isoindolinone and acts as a selective PARP-1 inhibitor with a Kd value of less than 0.01 μM. This compound is utilized in research related to cancer, cardiovascular diseases, neurological injuries, and inflammation.

Dimephosphon is an anti-inflammatory agent exhibiting both antihistamine and antiserotonin activities. It aids in maintaining spinal cord conduction function and reduces the excitability of motor neurons around lesion areas. Additionally, Dimephosphon directly stimulates lymph vessel movement, enhancing lymph circulation. This compound is useful for studying inflammatory edema, acute spinal cord injuries, and lymphatic circulation disorders.

EIDD-036 is a C-20 oxime of Progesterone capable of crossing the blood-brain barrier and binding to progesterone receptors (PR) with an IC50 value of 171 nM. It is the active metabolite of EIDD-1723 and has poor water solubility, making rapid administration in acute injuries challenging. EIDD-036 is applicable for traumatic brain injury (TBI) research.

Methylprednisolone Acetate(Depo-Medrate) has the ability to inhibit oxygen free radicals and can be used to treat acute spinal cord injuries.

Indomethacin sodium hydrate is an effective orally active, competitive, and reversible inhibitor of COX-1 and COX-2, with IC50 values of 18 nM and 26 nM, respectively. It possesses anti-inflammatory, anticancer, and antimicrobial activities and is commonly used in research related to cancer, inflammation, and viral infections. Additionally, it can induce migraines and gastrointestinal injury and is used to study increased intracranial pressure secondary to severe traumatic brain injury in adults, as well as rheumatoid arthritis. It can also be used to induce gastric ulcer models.

Isorhamnetin (3-methylquercetin) is the methylated metabolite of quercetin. Quercetin is an important dietary flavonoid with in vitro antioxidant activity. Isorhamnetin prevents endothelial cell injuries from oxidized LDL via inhibition of lectin-like ox-LDL receptor-1 upregulation, interference of ox-LDL-mediated intracellular signaling pathway (p38MAPK activation, NF-kappaB nuclear translocation, eNOS expression) and the antioxidant activity of isorhamnetin. Isorhamnetin prevents endothelial dysfunction, superoxide production, and overexpression of p47phox induced by angiotensin II. Isorhamnetin appears to be a potent drug against esophageal cancer due to it's in vitro potential to not only inhibit proliferation but also induce apoptosis of Eca-109 cells.

24:0 Lyso PC is a lysophosphatidylcholine lipid metabolite composed of the saturated fatty acid lignoceric acid (C24:0). The compound plays a role in regulating cell signaling and maintaining biological membrane integrity. It serves as an essential biomarker for investigating the pathophysiological processes of musculoskeletal and tendon injuries, aiming to assess the risk and severity of tissue damage through its fluctuating levels in the circulatory system.

Zofenopril calcium (SQ26991) is an antioxidant that acts as an angiotensin-converting enzyme inhibitor. ACE Zofenopril is a pro-drug designed to undergo metabolic hydrolysis yielding the active free sulfhydryl compound zofenoprilat, which is an angiotensin converting enzyme (ACE) inhibitor . Zofenopril promotes the regeneration of peripheral nerve injuries in rat models . Zofenopril increases SR calcium cycling and stimulates active calcium uptake into the SR .

(S)-4CPG ((S)-4-Carboxyphenylglycine) is a competitive mGlu1 receptor antagonist that attenuates nociceptive hypersensitivity and nociceptive abnormalities associated with sciatic nerve constriction injuries in rats, and may be used in the study of neurological disorders.

Phenazopyridine is an orally administered azo dye with local analgesic effects on urinary tract infections, causing urine to turn orange to red. Phenazopyridine exhibits micromolar-level inhibitory activity against SARM1 and TRPM8.

LYRM03 is an aminopeptidase inhibitor. LYRM03 is also an ubenimex derivative. LYRM03 attenuates LPS-induced acute lung injury in mice by suppressing the TLR4 signaling pathway. LYRM03 effectively attenuates LPS-induced ALI by inhibiting the expression of pro-inflammatory mediators and Myd88-dependent TLR4 signaling pathways in alveolar macrophages. LYRM03 may serve as a potential treatment for sepsis-mediated lung injuries.

TAT-NEP1-40 TFA, a blood-brain barrier-permeable peptide, safeguards PC12 cells against oxygen and glucose deprivation (OGD) and fosters neurite outgrowth. Additionally, it enhances neurological outcomes post-ischemia by curtailing apoptosis in ischemic cerebral tissues. This compound has utility in investigating central nervous system (CNS) injuries, encompassing axonal regeneration and functional recuperation following a stroke [1].

Trofinetide, derived from the neuroprotective tripeptide Gly-Pro-Glu (an N-terminal sequence of insulin-like growth factor-1, IGF-1), shows promise in various neuroprotective models. At a concentration of 10 nM, it mitigates cell death in primary rat embryonic striatal neurons caused by okadaic acid. Additionally, Trofinetide reduces the expression of pro-inflammatory markers (IL-1β, TNF-α, IL-6, and E-selectin) in a rat model simulating neuroinflammation from penetrating ballistic-like brain injuries. In cases of brain injury induced by middle cerebral artery occlusion (MCAO), administration of Trofinetide at 30 and 60 mg/kg reduces the area of cortical and striatal infarct. Furthermore, a daily dose of 100 mg/kg reverses social recognition and contextual fear conditioning deficits, diminishes the number of dendritic spines, and decreases testicular weight gain in an fmr1-/- knockout mouse model of fragile X syndrome. Trofinetide formulations have been employed in treating Rett syndrome, highlighting its versatility across various neurological conditions.

DCLK1-IN-5 (Compound a24), with an IC 50 of 179.7 nM, acts as a DCLK1 inhibitor. It mitigates lipopolysaccharide-induced inflammation by blocking DCLK1-mediated IKKβ phosphorylation. Additionally, DCLK1-IN-5 offers protection to mice from lung injuries and sepsis caused by inflammation [1].

TAK-218 is a candidate compound designed for use in treating central nervous system injuries and ischemia. It demonstrates significant radical scavenging activity and antioxidant properties. Additionally, TAK-218 inhibits the release of dopamine.

2-Oxo-zoniporide hydrochloride is an orally active type 1 sodium-hydrogen exchanger (NHE-1) inhibitor, utilized in the study of myocardial ischemic injuries.